Yahoo
NasdaqGS - Delayed Quote USD

Natera, Inc. (NTRA)

328.18 +0.51 (+0.16%)
At close: September 4 at 4:00:00 PM EDT
328.00 -0.18 (-0.05%)
After hours: September 4 at 7:47:16 PM EDT
Trade Natera on Coinbase
Chart Range Bar
Loading chart for NTRA
  • Previous Close 327.67
  • Open 323.92
  • Bid 298.30 x 200
  • Ask 353.21 x 200
  • Day's Range 323.42 - 329.05
  • 52 Week Range 157.43 - 343.18
  • Volume 968,221
  • Avg. Volume 1,385,123
  • Market Cap (intraday) 47.305B
  • Beta (5Y Monthly) 1.53
  • PE Ratio (TTM) --
  • EPS (TTM) -1.35
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 338.07

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

www.natera.com

6,135

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NTRA
43.25%
S&P 500 (^GSPC)
12.75%

1-Year Return

NTRA
97.03%
S&P 500 (^GSPC)
18.71%

3-Year Return

NTRA
424.92%
S&P 500 (^GSPC)
70.93%

5-Year Return

NTRA
165.17%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 752.75M
Earnings -66.97M
Profit Margin -8.90%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
-10.0%
-5.0%
0.0%
5.0%

Analyst Insights

View More

Analyst Price Targets

280.00 Low
338.07 Average
328.18 Current
376.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 315 -> 365

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -7.11%

  • Return on Assets (ttm)

    -8.08%

  • Return on Equity (ttm)

    -12.54%

  • Revenue (ttm)

    2.71B

  • Net Income Avi to Common (ttm)

    -192.35M

  • Diluted EPS (ttm)

    -1.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.09B

  • Total Debt/Equity (mrq)

    13.09%

  • Levered Free Cash Flow (ttm)

    104.03M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: